Goldman Sachs Group Inc Igm Biosciences, Inc. Put Options Transaction History
Goldman Sachs Group Inc
- $613 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding IGMS
# of Institutions
85Shares Held
19.8MCall Options Held
75KPut Options Held
35.9K-
Baker Bros. Advisors LP New York, NY4.09MShares$5.85 Million0.28% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.57MShares$5.1 Million0.0% of portfolio
-
Siren, L.L.C. New York, NY3.33MShares$4.76 Million0.9% of portfolio
-
Redmile Group, LLC San Francisco, CA2.95MShares$4.22 Million1.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA896KShares$1.28 Million0.0% of portfolio
About IGM Biosciences, Inc.
- Ticker IGMS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,969,000
- Market Cap $41.4M
- Description
- IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non...